Innovation & Collaboration: 2022 Advances in Musculoskeletal Oncology Symposium
Musculoskeletal oncology is constantly evolving with many varied treatment techniques applicable to many subspecialties. The providers, while focusing on their specialty must also be aware of new and evolving technologies and treatment techniques in subspecialties other than their own. The conference is intended to enhance the overall fund of knowledge required for these providers to treat patients in all subspecialties and to inform their colleagues on the availability and quality delivery of these technologies. With such emerging technologies, treatment techniques and clinical research trials, it is imperative that providers be aware of the best options for the patients they may encounter. This CE will address the gaps in these treatments, protocols and technologies to ensure the resources that are available to all providers is recognized in order to optimally collaborate care for each patient.
Keywords: Sarcoma, Musculoskeletal, connective tissue, neoplasm, healthcare delivery, patient care team, quality of life
Target Audience
- Radiation Oncologists
- Medical Oncologists
- Surgical Oncologists
- Radiologists
- Pathologists
- Residents
- Medical Students
- Advanced Practice Providers
Learning Objectives
Participants who engage in this educational intervention will be able to:
- Identify integral roles of the multidisciplinary team to be able to provide optimal care of musculoskeletal oncology patients.
- Describe current clinical trials in musculoskeletal oncology/novel agents in sarcoma. Attendees will be provided links to websites with up-to-date clinical trial information, to be able to best advise patients and increase enrollment in these trials.
- Appraise minimally-invasive options for patients with metastatic bone disease, including candidacy and workup. A panel discussion will reinforce and clarify learning.
- Critically review the data in latest management options, and potentially contribute to future research strategies by discussing with experts in this field.
- Create new networking opportunities with other health care providers, trainees and pharmaceutical partners.
- Develop collaborations that will lead to improve clinic trial portfolio and clinical trial participation.
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
John C Neilson
Gina D Amato
Danny Indelicato
Reena Singh
David King
Dennis Ian English
Callisia Clarke
Manpreet Bedi
Brandon Key
Andrew Rosenberg
Raphael Yechieli
Dao Nguyen
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest mitigation process and addressed.
Name | Company | Role |
---|---|---|
Sean M Tutton, MD | Boston Scientific/ BTG/ Galil | Consulting |
Robert G Maki, MD, PhD | Bayer Deciphera Glaxo S Smith Kline Karyopharm Peel Therapeutics PER: Physicians' Education Resource Tracon American Board of Internal Medicine American Society for Clinical Oncology UptoDate | Honorarium Honorarium Honorarium Honorarium Honorarium Honorarium Honorarium Honorarium Honorarium Consulting fees |
Adam Woolridge, MD MPH | Musculoskeletal Tumor Foundation | Honorarium |
Francis J Hornicek | FDA Stryker Medical Devices Bone Solutions Inc. Globus Medical | Government Drug Regulation- Safety Committee Member Consultant Stock/Shareholder Royalties on Colloseum Anterior Cage |
Susan V Bukata | Radius Solarea Amgen | Honorarium Consultant Consultant |
John Charlson | Deciphera | Consultant |
Available Credit
- 8.50 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 8.50 Hours of ParticipationHours of Participation credit.